Filing Flows › Comparisons › NWBO vs UPB
Northwest Biotherapeutics vs Upstream Bio: NWBO and UPB compared
Northwest Biotherapeutics is the larger company: $807K of revenue in its latest quarter (Q2 2026) against $773K for Upstream Bio (Q2 2026). Northwest Biotherapeutics is growing faster (+516% against -18% a year earlier).
Where the money goes: NWBO and UPB
Northwest Biotherapeutics (NWBO) · Q2 2026
Northwest Biotherapeutics, Q2 2026: revenue $807K (+516% year over year), net loss $15.4M, operating cash flow −$7.2M. The chart follows the revenue to costs, profit and cash.
Upstream Bio (UPB) · Q2 2026
Upstream Bio, Q2 2026: revenue $773K (-18% year over year), net loss $39.7M, operating cash flow −$35.6M. The chart follows the revenue to costs, profit and cash.
| Northwest Biotherapeutics (NWBO) | Upstream Bio (UPB) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $807K | $773K |
| Revenue growth, Y/Y | +516% | -18% |
| Operating margin | n/m | n/m |
| Net earnings | −$15.4M | −$39.7M |
| Operating cash flow | −$7.2M | −$35.6M |
Questions
Which is bigger, Northwest Biotherapeutics or Upstream Bio?
Northwest Biotherapeutics is the larger company: $807K of revenue in its latest quarter (Q2 2026) against $773K for Upstream Bio (Q2 2026).
Is Northwest Biotherapeutics or Upstream Bio growing faster?
Northwest Biotherapeutics is growing faster (+516% against -18% a year earlier).
More: Northwest Biotherapeutics earnings · how Northwest Biotherapeutics makes money · Upstream Bio earnings · how Upstream Bio makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 14, 2026; 10-Q filed Aug 11, 2026). Fiscal quarters can end on different dates. Not investment advice.